ESMO® 2026 Highlights: Presenter Vignettes – Federico Cappuzzo

Dr. Federico Cappuzzo

Federico Cappuzzo

MD

National Cancer Institute Regina Elena

2661RO

Results of a multicenter, phase II, open-label, randomized trial evaluating OSE2101 plus docetaxel or OSE2101 plus nivolumab as second-line therapy in metastatic non-small-cell lung cancer (NSCLC) progressing after first-line chemo-immunotherapy